Multiple Sclerosis Symptoms Aggravated By Genetic Alterations in Patients

Click here to receive MS news via e-mail
genetic alteration in MS

genetic alteration in MSWhile the majority of scientists dedicated to multiple sclerosis research focus on genetic regulators of conditions such as autoimmunity, demyelination, inflammation, and neurodegeneration, a team from the University of Lubeck in Germany, led by Saleh M. Ibrahim, MD, PhD, focuses on genetic regulators of conduction velocity. The team is uncovering how certain genetic alterations aggravate disease in multiple sclerosis patients and mice with multiple sclerosis-like experimental autoimmune encephalomyelitis (EAE).

“Impairment of nerve conduction is a common feature in neurodegenerative and neuroinflammatory diseases such as multiple sclerosis,” stated Dr. Ibrahim, as reported by a press release from the publishing organization Elsevier. “Measurement of evoked potentials (whether visual, motor, or sensory) is widely used for diagnosis and recently also as a prognostic marker for multiple sclerosis.”

The gene culprit identified by Dr. Ibrahim’s group is the inositol polyphosphate-4-phosphatase, type II (INPP4b) gene. As detailed in the team’s article published in The American Journal of Pathology, “Nerve Conduction Velocity is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene,” polymorphisms, or two variants of the same gene, of Inpp4b produce different speeds of nerve conduction in multiple sclerosis patients and mice with EAE.

Dr. Ibrahim and colleagues made their discovery through several genomic approaches, including quantitative trait mapping, congenic mapping, in silico haplotype analyses, comparative genomics, and transgenic mice. After identifying Inpp4b as the gene behind the genetic locus EAE31, which was previously shown to control motor evoked potential latency and clinical onset of mouse EAE, the team analyzed the region in 8 mice strains.

Interestingly, the strains of mice could be placed into two categories based on the resultant amino acid sequence of INPP4B. One groups had the longer-latency SJL/J allele and the two amino acids arginine and proline, while the other group had the shorter-latency C57BL/10S allele and the two amino acids serine and histidine. “These data suggest that INPP4b structural polymorphism is associated with the speed of neuronal conduction,” stated Dr. Ibrahim. What’s more, mice with mutant Inpp4b had slower nerve conduction than control mice without the mutation.

Applying their findings to humans, the team investigated INPP4B polymorphisms in multiple sclerosis patients from Spain and Germany. Each group had over 300 cases of the mutation and controls (349 cases and 362 controls in Spain and 562 cases and 3,314 controls in Germany). When the cohorts were pooled, there was a statistical significance in the risk for aggravated multiple sclerosis symptoms due to a INPP4B polymorphism. However, looking at the cohorts individually, the Spanish cohort showed a significant association, while the German cohort did not. “The exact reason for the diverging effect across these populations remains unresolved,” commented Dr. Ibrahim.

[adrotate group=”4″]

Other researchers are taking note of the team’s work. In the same issue of The American Journal of Pathology, Hans Lassmann, MD, from the Center for Brain Research of the Medical University of Vienne in Austria, wrote a commentary entitled “Genetic Control of Nerve Conduction Velocity May Influence Multiple Sclerosis Phenotype.”

“This study represents an interesting example of how minor changes in conduction velocity, which do not result in a clinical phenotype in control populations, may aggravate disease in conditions such as EAE or MS,” wrote Dr. Lassmann. While the polymorphism itself may not induce disease on its own, it can certainly aggravate symptoms of multiple sclerosis. No other hallmarks of multiple sclerosis, such as major myelin loss, were identified in mice with mutant alleles, but it is still unclear which neurobiological mechanisms underlie the INPP4B-associated impaired conduction.

INPP4B helps regulate the phosphatidyl inositol signaling pathway, which controls cell growth, proliferation, differentiation, motility, survival, and intracellular communication. It is possible INPP4B is involved in calcium ion signaling between neural synapses, which may affect neurotransmitter release. Neurotransmitters are involved in nerve conduction and neural communication, both of which are strongly affected in multiple sclerosis.

Tagged , .

Maureen Newman is a science columnist for BioNews Texas. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.
Click here to receive MS news via e-mail

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *